Neurocentria Inc

Neurocentria is a clinical stage San Francisco area-based pharmaceutical company striving to develop treatments primarily for neurodegenerative diseases such as Mild Cognitive Impairment and Alzheimer’s Disease. Currently, we have positive Phase II data demonstrating strong efficacy and safety for treating Alzheimer’s Disease with our primary candidate compound, and we are set to launch Phase III clinical trials. While we are quickly moving forward with late-stage clinical trials on this first-generation compound in neurodegenerative diseases, we wish to develop the next generation of products and expand our pipeline. We have recently begun investigating therapies for infectious disease, particularly those related to immune dysfunction.